Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Novavax Inc

NASDAQ: NVAX · Life Sciences · 3 alerts · CIK 1000694

Share price
$8.06Close, Nov 16
Market cap
$1.33B
Shares outstanding
165.01MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Novavax Inc filings on SEC EDGAR ↗

8:28 AM ET 10-Q
Financial Results

Novavax Q3 2026 Results: Net Loss of $31.4M, Loss Narrows

Novavax reported total revenue of $68.3 million for the third quarter of 2026, a slight decrease from $70.4 million in the prior year, while net loss narrowed significantly to $31.4 million compared to $202.4 million. For the nine-month period, the company experienced a net loss of $94.3 million, a sharp reversal from the $422.8 million net income recorded in the same period of 2025, primarily due to a substantial drop in product sales and licensing revenue.

Key figure
Net loss $31.4M
8:09 AM ET 8-K
Financial Results

Novavax Financial Results

Novavax reported Q3 2026 total revenue of $68 million and raised its full-year 2026 revenue guidance to $400 million at the mid-point. The company also earned a $125 million milestone payment from partner Sanofi following the initiation of a Phase 3 combination vaccine trial in Europe.

“This quarter, we continued to execute across all three pillars of our strategy. Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment. Our focused R&D efforts are building a growing body of data on what our technology can do in infectious disease, advancing our C. difficile candidate towards the clinic and exploring oncology as a potential new area of application. And we have been doing this while continuing to reduce expenses and operate with financial discipline. Over time, we believe this strategy can build a robust and profitable Novavax, with multiple partners and products, diversified revenue streams and a meaningful impact on global health.”

John C. Jacobs, President and Chief Executive Officer, Novavax

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.